OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock
Trends in cancer (2020) Vol. 7, Iss. 1, pp. 15-28
Open Access | Times Cited: 83
Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock
Trends in cancer (2020) Vol. 7, Iss. 1, pp. 15-28
Open Access | Times Cited: 83
Showing 1-25 of 83 citing articles:
Delivering precision oncology to patients with cancer
Joaquı́n Mateo, Lotte Steuten, Philippe Aftimos, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 658-665
Closed Access | Times Cited: 241
Joaquı́n Mateo, Lotte Steuten, Philippe Aftimos, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 658-665
Closed Access | Times Cited: 241
Clinical trial design in the era of precision medicine
Elena Fountzilas, Apostolia M. Tsimberidou, Henry Hiep Vo, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 160
Elena Fountzilas, Apostolia M. Tsimberidou, Henry Hiep Vo, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 160
The coming decade in precision oncology: six riddles
Adam Wahida, Lars Buschhorn, Stefan Fröhling, et al.
Nature reviews. Cancer (2022) Vol. 23, Iss. 1, pp. 43-54
Closed Access | Times Cited: 141
Adam Wahida, Lars Buschhorn, Stefan Fröhling, et al.
Nature reviews. Cancer (2022) Vol. 23, Iss. 1, pp. 43-54
Closed Access | Times Cited: 141
Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory
Hartmut Beck, Michael Härter, B. Hass, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 6, pp. 1560-1574
Open Access | Times Cited: 110
Hartmut Beck, Michael Härter, B. Hass, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 6, pp. 1560-1574
Open Access | Times Cited: 110
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 614-614
Open Access | Times Cited: 47
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 614-614
Open Access | Times Cited: 47
Novel clinical trial designs emerging from the molecular reclassification of cancer
Mina Nikanjam, Shumei Kato, Teresa Allen, et al.
CA A Cancer Journal for Clinicians (2025)
Open Access | Times Cited: 3
Mina Nikanjam, Shumei Kato, Teresa Allen, et al.
CA A Cancer Journal for Clinicians (2025)
Open Access | Times Cited: 3
SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy
Kristina Mardinian, Jacob J. Adashek, Gregory P. Botta, et al.
Molecular Cancer Therapeutics (2021) Vol. 20, Iss. 12, pp. 2341-2351
Open Access | Times Cited: 56
Kristina Mardinian, Jacob J. Adashek, Gregory P. Botta, et al.
Molecular Cancer Therapeutics (2021) Vol. 20, Iss. 12, pp. 2341-2351
Open Access | Times Cited: 56
Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe
Denis Horgan, Giuseppe Curigliano, Olaf Rieß, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 1, pp. 72-72
Open Access | Times Cited: 47
Denis Horgan, Giuseppe Curigliano, Olaf Rieß, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 1, pp. 72-72
Open Access | Times Cited: 47
The abscopal effect in patients with cancer receiving immunotherapy
Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, et al.
Med (2023) Vol. 4, Iss. 4, pp. 233-244
Open Access | Times Cited: 30
Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, et al.
Med (2023) Vol. 4, Iss. 4, pp. 233-244
Open Access | Times Cited: 30
Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours
Sophie O’Haire, Fanny Franchini, Yoon‐Jung Kang, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 28
Sophie O’Haire, Fanny Franchini, Yoon‐Jung Kang, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 28
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives
Alfredo Addeo, Ernesto G. Miranda-Morales, Petra den Hollander, et al.
Pharmacology & Therapeutics (2023) Vol. 242, pp. 108344-108344
Open Access | Times Cited: 26
Alfredo Addeo, Ernesto G. Miranda-Morales, Petra den Hollander, et al.
Pharmacology & Therapeutics (2023) Vol. 242, pp. 108344-108344
Open Access | Times Cited: 26
N-of-1 Trials in Cancer Drug Development
Mohamed A. Gouda, Lars Buschhorn, Andreas Schneeweiß, et al.
Cancer Discovery (2023) Vol. 13, Iss. 6, pp. 1301-1309
Open Access | Times Cited: 24
Mohamed A. Gouda, Lars Buschhorn, Andreas Schneeweiß, et al.
Cancer Discovery (2023) Vol. 13, Iss. 6, pp. 1301-1309
Open Access | Times Cited: 24
If it’s a target, it’s a pan-cancer target: Tissue is not the issue
Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102721-102721
Open Access | Times Cited: 12
Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102721-102721
Open Access | Times Cited: 12
Fusion genes in pancreatic tumors
Αναστάσιος Γκουντάκος, Aatur D. Singhi, C. Benedikt Westphalen, et al.
Trends in cancer (2024) Vol. 10, Iss. 5, pp. 430-443
Open Access | Times Cited: 10
Αναστάσιος Γκουντάκος, Aatur D. Singhi, C. Benedikt Westphalen, et al.
Trends in cancer (2024) Vol. 10, Iss. 5, pp. 430-443
Open Access | Times Cited: 10
Omics-based molecular classifications empowering in precision oncology
Zhaokai Zhou, Ting Lin, Shuang Chen, et al.
Cellular Oncology (2024) Vol. 47, Iss. 3, pp. 759-777
Closed Access | Times Cited: 9
Zhaokai Zhou, Ting Lin, Shuang Chen, et al.
Cellular Oncology (2024) Vol. 47, Iss. 3, pp. 759-777
Closed Access | Times Cited: 9
Tumour-agnostic kinase inhibitors
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 1
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 1
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies
Antonio Russo, Lorena Incorvaia, Umberto Malapelle, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 165, pp. 103436-103436
Closed Access | Times Cited: 45
Antonio Russo, Lorena Incorvaia, Umberto Malapelle, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 165, pp. 103436-103436
Closed Access | Times Cited: 45
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
Antonio Matrone, Carla Gambale, Alessandro Prete, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 33
Antonio Matrone, Carla Gambale, Alessandro Prete, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 33
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
Jacob J. Adashek, Arjun K. Menta, Neha K. Reddy, et al.
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 6, pp. 871-878
Open Access | Times Cited: 33
Jacob J. Adashek, Arjun K. Menta, Neha K. Reddy, et al.
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 6, pp. 871-878
Open Access | Times Cited: 33
PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers
Ethan S. Sokol, Dexter X. Jin, Alexander D. Fine, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 30
Ethan S. Sokol, Dexter X. Jin, Alexander D. Fine, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 30
Revolutionizing cancer drug development: Harnessing the potential of basket trials
Vivek Subbiah, Howard A. Burris, Razelle Kurzrock
Cancer (2023) Vol. 130, Iss. 2, pp. 186-200
Closed Access | Times Cited: 19
Vivek Subbiah, Howard A. Burris, Razelle Kurzrock
Cancer (2023) Vol. 130, Iss. 2, pp. 186-200
Closed Access | Times Cited: 19
Hallmarks of RET and Co-occuring Genomic Alterations inRET-aberrant Cancers
Jacob J. Adashek, Aakash Desai, Alexander Andreev-Drakhlin, et al.
Molecular Cancer Therapeutics (2021) Vol. 20, Iss. 10, pp. 1769-1776
Open Access | Times Cited: 36
Jacob J. Adashek, Aakash Desai, Alexander Andreev-Drakhlin, et al.
Molecular Cancer Therapeutics (2021) Vol. 20, Iss. 10, pp. 1769-1776
Open Access | Times Cited: 36
Cancer: slaying the nine-headed Hydra
Jacob J. Adashek, Vivek Subbiah, C. Benedikt Westphalen, et al.
Annals of Oncology (2022) Vol. 34, Iss. 1, pp. 61-69
Open Access | Times Cited: 26
Jacob J. Adashek, Vivek Subbiah, C. Benedikt Westphalen, et al.
Annals of Oncology (2022) Vol. 34, Iss. 1, pp. 61-69
Open Access | Times Cited: 26
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
Amol Gupta, Razelle Kurzrock, Jacob J. Adashek
Cancers (2023) Vol. 15, Iss. 5, pp. 1578-1578
Open Access | Times Cited: 16
Amol Gupta, Razelle Kurzrock, Jacob J. Adashek
Cancers (2023) Vol. 15, Iss. 5, pp. 1578-1578
Open Access | Times Cited: 16
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer
Jacob J. Adashek, Chinmayi Pandya, Nicholas J. Maragakis, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Jacob J. Adashek, Chinmayi Pandya, Nicholas J. Maragakis, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
